Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Serrated Polyp, Hyperplastic Polyp, Sessile Serrated Adenoma, Colorectal Cancer
Interventions: Mobio PowerSoil DNA Isolation Kit; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: CK-1827452, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: San Diego, California • Newark, Delaware

Conditions: Drug-drug Interaction
Interventions: PBI-200 Tablet, Ritonavir Oral Tablet, Cobicistat Oral Tablet; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Appendicitis
Interventions: MRI of the abdomen; Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Zelquistinel 3 mg, Zelquistinel 10 mg; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: B-cell Non-Hodgkin Lymphoma, Aggressive
Interventions: collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT; Other · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 12
States / cities: Miami, Florida • Rochester, Minnesota • Basking Ridge, New Jersey + 8 more

Conditions: Healthy Volunteer
Interventions: eliglustat; digoxin, digoxin; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, gemcitabine hydrochloride, imatinib mesylate, mutation analysis, nucleic acid sequencing, polymerase chain reaction; Drug · Genetic
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Covid19
Interventions: Whole exome sequencing; Genetic
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: Staccato alprazolam, Oral alprazolam; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
Interventions: CONVIVO system, Conventional histologic evaluation; Diagnostic Test · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Preterm Birth
Interventions: Exercise; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 31
States / cities: Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more

Conditions: Malignant Hyperthermia
Interventions: Whole exome sequencing; Genetic
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
Interventions: Follow-Up, Medical Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2044
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Injuries
Interventions: Acute Intermitted Hypoxia, Massed Practise, Rapael Glove; Other · Procedure
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • East Hanover, New Jersey

Conditions: Surgery, Surgical Procedures, Minimally Invasive, Training, Training Effectiveness, Learning Curve
Interventions: Surgical video grading; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: GSK1349572, Placebo, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Transplant
Interventions: Generic Tacrolimus, Branded Tacrolimus; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Hemiparesis;Poststroke/CVA
Interventions: Joint mobilization; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 21 Years to 86 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 260
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 221 more

Conditions: Accidental Falls/Prevention and Control, Osteoporosis
Interventions: Deprescribing Care Model, Bone Health Service Model, Injury Prevention Service Model; Other
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 3,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Search by objective public record fields.

Study of Gut Microbiome and Colorectal Tumors

A Study of CK-1827452 Infusion in Stable Heart Failure

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

Magnetic Resonance Imaging (MRI) of Appendicitis in Children

Pharmacokinetics of Zelquistinel in Fasted or Fed State

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Evaluation of the CONVIVO System

Mitochondrial DNA Signatures of Poor Aerobic Exercise Trainability in Young Adults Born Preterm

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Malignant Hyperthermia Registry and Genetic Testing

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

A Multi-Center Clinical Trial in Individuals With Spinal Cord Injury

Hydrus Learning Curve Study

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

Immediate Effect of Ankle Mobilization on Active Range of Motion and Gait in Subacute Stroke

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications